As prescription opioid overdoses rise in the U.S., the Prime/MRx Special Investigations Unit (SIU) shares how to identify if someone has overdosed and how you can help save a life

Someone holds a GLP-1 pen needle in their hands.

Effective: January 2021 Terms of use IF YOU ARE EXPERIENCING A MEDICAL EMERGENCY, DIAL 911 AND/OR SEEK IMMEDIATE ATTENTION FROM A HEALTH CARE PROVIDER. THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE....

Kresladi, by Rocket Pharmaceuticals, is undergoing it’s second review by the FDA for the treatment of severe leukocyte adhesion deficiency type 1 (LAD-1). In June 2024, the FDA issued a CRL for...

Principal Financial Systems - Remote Job description: The Process Improvement Project Analyst Principal is responsible for directing a wide variety of initiatives to achieve significant financial,...

PTC Therapeutics is awaiting the FDA decision for ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The FDA granted ataluren Fast Track and Orphan Drug...

June 29, 2026: oxylanthanum carbonate Veligrotug is an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody developed by Viridian and submitted to the FDA for the treatment of thyroid eye...

Polaris is awaiting an FDA decision for pegargiminase, an arginine degrading enzyme, for the treatment of malignant pleural mesothelioma (MPM) with non-epithelioid histology. The FDA granted the...

References 1. U.S. Food and Drug Administration. Application number 761381: Opdivo Qvantig (nivolumab and hyaluronidase-nvhy). Drugs@FDA. Accessed February 6, 2026....

As opioid overdose deaths increase across the country, Aug. 31 recognizes those lost to overdose and encourages education and advocacy.

Prerak Parikh, PharmD, was recently named an Emerging Leader in Healthcare by Managed Healthcare Executive.

The American Journal of Managed Care (AJMC): The growing list of insurers dropping coverage for costly GLP-1 weight loss drugs leaves patients to bear even higher out-of-pocket expenses while still...

The FDA granted a Priority Review for zoliflodacin, a first-in-class, spiropyrimidinetrione oral antibiotic by Innoviva, for the treatment of uncomplicated gonorrhea in adults and pediatric...

Publications High Cost Therapy Profile: October 2024 Eladocagene Exuparvovec October 15, 2024 References PTC Therapeutics announces FDA acceptance and Priority Review of the BLA for UpstazaTM. PTC...

Jessica Johnson, clinical consultant, shares how to identify and prevent opioid overdoses

Novartis submitted an application to the FDA in 2Q 2025 for an intrathecal formulation (OAV101IT) of their one-time gene therapy onasemnogene abeparvovec (OAV101IT) for the treatment of spinal...

PUBLICATIONS FDA Decisions Expected: January 2026 Your monthly synopsis of new drugs expected to hit the market All brand names are property of their respective owners. References SERENA-6 trial:...

PUBLICATIONS FDA Decisions Expected: February 2025 Drug pipeline for February 2025 Your monthly synopsis of new drugs expected to hit the market At Prime Therapeutics (Prime), we have positioned...

In this special episode of the Pharmacy Friends podcast, the CEOs of Prime Therapeutics, Mostafa Kamal, and Capital Rx, AJ Loiacono, join Michael Passanante, SVP of Marketing & Communications at...

Dec. 28, 2024: cosibelimab Checkpoint Therapeutics resubmitted an application for its anti-programmed death ligand-1 (PD-L1) antibody, cosibelimab, for the treatment for adults with metastatic or...